Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MEI Pharma, Inc. - Common Stock (NQ:MEIP)

3.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MEI Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’
From Lite Strategy, Inc.
Via Business Wire
MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising
From MEI Pharma, Inc.
Via Business Wire
BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with &quot;capital + technology&quot; dual-driven mode
Via TheNewswire.com
Topics ETFs
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Fiscal Year End 2024 Cash Position
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Consider Strategic Alternatives
From MEI Pharma, Inc.
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
From Glancy Prongay & Murray LLP
Via Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
From MEI Pharma, Inc.
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
From Glancy Prongay & Murray LLP
Via Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
From MEI Pharma, Inc.
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
From Glancy Prongay & Murray LLP
Via Business Wire
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Recommends Stockholders Not to Consent
From MEI Pharma
Via Business Wire
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.